The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes
- PMID: 34976741
- PMCID: PMC8688704
- DOI: 10.1016/j.jcte.2021.100287
The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes
Abstract
Cystic fibrosis related diabetes (CFRD) generally reflects insufficient and/or delayed production of insulin, developing slowly over years to decades. Multiple mechanisms have been implicated in the pathogenesis of CFRD. CFTR function itself is a strong determinant of CFRD risk. Variants in CFTR that result in residual CFTR function and exocrine pancreatic sufficiency reduce the risk of CFRD by ten to twenty fold. Two groups of hypotheses have been proposed for the mechanism of CFTR impairing insulin secretion in CFRD: (1) β-cell dysfunction results from β cell intrinsic CFTR-dependent mechanisms of insulin secretion. (2) β-cell dysfunction results from factors outside the β cell. Genome-wide association studies have identified multiple susceptibility genes for type 2 diabetes, including TCF7L2, CDKN2A/B, CDKAL1, and IGF2BP2, as containing genetic modifiers of CFRD. These findings support the presence of intrinsic β cell defects playing a role in CFRD pathogenesis. Oxidative stress and inflammation are β cell-extrinsic mechanisms involved with CFRD. CFTR mutations render β cells more susceptible to oxidative stress and also leads to defects in α-cell function, resulting in reduced suppression of glucagon secretion. Furthermore, CFRD is characterized by β cell loss secondary to intra-islet inflammation. Recent studies have demonstrated the presence of multiple inflammatory mediators within the human CF islet. This review presents a concise overview of the current understanding of genetic modifiers of CFRD, oxidative stress, islet inflammation, and the controversies about the role of CFTR in the islet.
Keywords: CFTR; Genetic modifiers; β cell.
© 2021 The Authors. Published by Elsevier Inc.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The Potential Causes of Cystic Fibrosis-Related Diabetes.Front Endocrinol (Lausanne). 2021 Jul 30;12:702823. doi: 10.3389/fendo.2021.702823. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34394004 Free PMC article. Review.
-
Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits.J Clin Endocrinol Metab. 2020 May 1;105(5):1401-15. doi: 10.1210/clinem/dgz102. J Clin Endocrinol Metab. 2020. PMID: 31697830 Free PMC article.
-
Islet-intrinsic effects of CFTR mutation.Diabetologia. 2016 Jul;59(7):1350-1355. doi: 10.1007/s00125-016-3936-1. Epub 2016 Mar 31. Diabetologia. 2016. PMID: 27033560 Free PMC article. Review.
-
Islet Function in the Pathogenesis of Cystic Fibrosis-Related Diabetes Mellitus.Clin Med Insights Endocrinol Diabetes. 2021 Jul 13;14:11795514211031204. doi: 10.1177/11795514211031204. eCollection 2021. Clin Med Insights Endocrinol Diabetes. 2021. PMID: 34345195 Free PMC article. Review.
-
Cystic fibrosis-related diabetes is caused by islet loss and inflammation.JCI Insight. 2018 Apr 19;3(8):e98240. doi: 10.1172/jci.insight.98240. eCollection 2018 Apr 19. JCI Insight. 2018. PMID: 29669939 Free PMC article.
Cited by
-
ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.Pediatr Diabetes. 2022 Dec;23(8):1212-1228. doi: 10.1111/pedi.13453. Pediatr Diabetes. 2022. PMID: 36537525 Free PMC article. No abstract available.
-
Pancreatic Crosstalk in the Disease Setting: Understanding the Impact of Exocrine Disease on Endocrine Function.Compr Physiol. 2024 Mar 29;14(2):5371-5387. doi: 10.1002/cphy.c230008. Compr Physiol. 2024. PMID: 39109973 Free PMC article. Review.
-
Oxidative Stress Biomarkers in Cystic Fibrosis and Cystic Fibrosis-Related Diabetes in Children: A Literature Review.Biomedicines. 2023 Sep 29;11(10):2671. doi: 10.3390/biomedicines11102671. Biomedicines. 2023. PMID: 37893045 Free PMC article. Review.
-
Metabolic Syndrome and Tendon Disease: A Comprehensive Review.Diabetes Metab Syndr Obes. 2024 Apr 9;17:1597-1609. doi: 10.2147/DMSO.S459060. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38616994 Free PMC article. Review.
References
-
- Lohr M., Goertchen P., Nizze H., Gould N.S., Gould V.E., Oberholzer M., et al. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study. Virchows Arch A Pathol Anat Histopathol. 1989;414(2):179–185. - PubMed
-
- Iannucci A., Mukai K., Johnson D., et al. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol. 1984;15:278–284. - PubMed
-
- Abdul-Karim F., Dahms B., Velasco M., et al. Islets of Langerhans in adolescents and adults with cystic fibrosis. A quantitative study. Arch Pathol Lab Med. 1986;110:602–606. - PubMed
-
- Soejima K., Landing B. Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies. Pediatr Pathol. 1986;6:25–46. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous